$Esperion Therapeutics (ESPR.US)$Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share. Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
$Esperion Therapeutics (ESPR.US)$Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry: 1. Unique Market Position in Statin Alternatives – Addressing Statin Intolerance: There are millions of statin...
$Esperion Therapeutics (ESPR.US)$$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
6
9
1
Report
Millaai
:
You're under duvet, are you looking for a successor everywhere
Growth Investor27
Millaai
:
The author has been buying below $2 so your comment is off. This research article has all the due diligence to see, other than the fact Institutions have been heavly buying this year, fintel shows now 74% owned. ESPR is a good investment.
Detached House
Millaai
:
You are wrong. Though short term looks like the price is consolidating, the weekly chart looks promising! So look at the chart to see if it aligns with the fundamentals before criticising others!
This unique biotech$Esperion Therapeutics (ESPR.US)$Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
14
1
4
Report
10xStockPicks
OP
:
This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Novartis AG Stock Forum
Breakthrough: Novartis Scores Historic FDA Approval for Rare Kidney Disease Treatment
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
No comment yet